Abstract
The opinion that schizophrenia is a heterogenous disease goes back to E. Bleuler who in his monograph Dementia Praecox oder Gruppe der Schizofrenien (Bleuler 1911) proposed the term schizophrenia in his psychopathological descriptions of patients with dementia praecox. In his textbook Lehrbuch der Psychiatrie he writes: “Wenn wir auch eine naturliche innere Einteilung noch nicht machen konnen, so erscheint uns die Schizophrenie doch nicht als eine Krankheit im engeren Sinne, sondern als eine Krankheitsgruppe, etwa analog der Gruppe der Organischen, die in Paralyse, senile Formen usw. Zerfällt. Man sollte deswegen eigentlich von Schizophrenien in der Mehrzahl sprechen” (Since we cannot divide schizophrenia on objective grounds, schizophrenia seems not to be one disease, but rather a group of disorders, more like the organic psychoses - paralysis, dementia. One should conceive of schizophrenia in plural.) (Bleuler 1916) However, in previous research most investigators have conceived schizophrenia as a uniform disease with Kraepelin’s subtypes, i. e., catatonic, paranoid, and hebephrenic schizophrenia. Over the years several different diagnostic systems have been developed and used in schizophrenia research. This means that different criteria for selection of patients in research have been used, suggesting that quite different patient categories have been studied. Thus Brockington et al. (1978), using 10 diagnostic systems in the study of 119 psychotic patients, found that the number of patients with a diagnosis of schizophrenia ranged between 4% and 45%.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Alfredsson G, Wiesel F-A (1990) Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients. Psychopharmacology (Berl) 101: 324–331
Andreasen NC (1982) Negative symptoms in schizophrenia. Arch Gen Psychiatry 39: 784–788
Angst J, Stassen HH, Woggon B (1989) Effect of neuroleptics on positive and negative symptoms and the deficit state. Psychopharmacology (Berl) 99: S41–S46
Bleuler E (1911) Dementia praecox oder Gruppe der Schizophrenien. Deuticke, Leipzig
Bleuler E (1916) Lehrbuch der Psychiatrie. Springer, Berlin
Bowers MB Jr, Swiger ME, Jatlow PI, Hoffman FJ, Giocoechea N (1986) Early neuroleptic response in psychotic men and women: correlation with plasma HVA and HMPG. Compr Psychiatry 27: 181–185
Brockington IF, Kendell RE, Leff JP (1978) Definitions of schizophrenia: concordance and prediction of outcome. Psychol Med 8: 387–398
Carlsson M, Carlsson A (1990) Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr Bull 16 (3): 425–432
Chang W-H, Chen T-Y, Lee C-F, Hung J-C, Hu W-H, Yeh E-K (1988) Plasma homovanillic acid levels and subtyping of schizophrenia. Psychiatry Res 23: 239–244
Cheramy A, Romo R, Godeheu C, Baruch P, Glowinski J (1986) In vivo presynaptic control of dopamine release in the cat caudate nucleus-II. Facilitatory or inhibitory influence of Lxglutamate. Neuroscience 19: 1081–1090
Crow TJ (1980) Molecular pathology of schizophrenia: more than one disease process? Br Med J 66–68
Farde L, Wiesel F-A, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71–76
Farde L, Wiesel F-A, Stone-Elander S, Halldin C, Nordström A-L, Hall H, Sedvall G (1990) D2-Dopamine receptors in neuroleptic-naive schizophrenic patients - a PET- study with (11C)raclopride. Arch Gen Psychiatry 47: 213–219
Fonnum F (1984) Glutamate: a neurotransmitter in mammalian brain. J Neurochem 42: 1–11
Gattaz WF, Kohlmeyer K, Gasser T (1990) Computer tomographic studies in schizophrenia. In: Häfner H, Gattaz WF (eds) Search for the causes of schizophrenia, vol 2. Springer, Berlin Heidelberg New York, pp 242–256
Hagenfeldt L, Venizelos N, Bjerkenstedt L, Wiesel F-A (1987) Decreased tyrosine transport in fibroblasts from schizophrenic patients. Life Sci 41: 2749–2757
Johnstone EC, Crow TJ, Frith CD, Husband J, Kreel L (1976) Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet 2: 924–926
Kane J, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796
Kay SR, Singh MM (1989) The positive-negative distinction in drug-free schizophrenic patients. Arch Gen Psychiatry 46: 711–718
Keks NA, Copolov DL, Kulkarni J, Mackie B, Singh BS, McGorry P, Rubin RT, Hassett A, McLaughlin M, van Riel R (1990) Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems. Biol Psychiatry 27: 1203–1215
Kennedy JL, Giuffra LA, Moises HW, Cavalli-Sforza LL, Pakstis AJ, Kidd JR, Castiglione CM, Sjögren B, Wetterberg L, Kidd KK (1988) Evidence against linkage of schizophrenia to markers on chromosome 5 in a northern Swedish pedigree. Nature 336: 167–170
Kornhuber HH, Kornhuber I, Kim JS, Kornhuber ME (1984) Zur biochemischen Theorie der Schizophrenic (A biochemical theory of schizophrenia). Nervenarzt 55: 602–606
McDermott BE, Sautter FJ, Garver DL (1991) Heterogeneity of schizophrenia: relationship to latency of neuroleptic response. Psychiatry Res 37: 97–103
Roberts PJ, McBean GJ, Sharif NA, Thomas EM (1982) Striatal glutamatergic function: modifications following specific lesions. Brain Res 235: 83–91
Sherrington R, Brynjolfsson J, Petursson H, Potter M, Dudleston K, Barraclough B, Wasmuth J, Dobbs M, Gurling H (1988) Localization of a susceptibility locus for schizophrenia on chromosome 5. Nature 336: 164–167
Strauss JS, Gift TE (1977) Choosing an approach for diagnosing schizophrenia. Arch Gen Psychiat 34: 1248–1253
Weinberger DR (1990) Brain anatomy in schizophrenia. Discussion. In: Häfner H, Gattaz WV (eds) Search for the causes of schizophrenia, vol 2. Springer, Berlin, Heidelberg New York, pp 275–281
Wiesel F-A (1989) Positron-emission tomography in psychiatry. Psychiatr Dev 1: 19–47
Wiesel F-A, Farde L, Nordström A-L, Sedvall G (1990) Central D1- and D2 receptor occupancy during antipsychotic drug treatment. Proc NeuroPsychopharmacol Biol Psychiatry 14: 759–767
Wiesel F-A, Blomqvist G, Venizelos N, Bjerkenstedt L, Halldin C, Hagenfeldt L, Sjögren I (1991) Altered transport of tyrosine across the blood brain barrier in patients with schizophrenia. Biol Psychiatry 2: 337–340
Wik G, Wiesel F-A, Sjögren I, Blomqvist G, Greitz T, Stone-Elander S (1989) Effects of sulpiride and chlorpromazine on regional cerebral glucose metabolism in schizophrenic patients as determined by positron emission tomography. Psychopharmacology (Berl) 97: 309–318
Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue C-Y, Cooper TB, Brodie JD (1989) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 146: 905–908
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Wiesel, FA. (1993). Neuroleptics and Diagnostic Heterogeneity in Relation to Drug Evaluation. In: Gram, L.F., Balant, L.P., Meltzer, H.Y., Dahl, S.G. (eds) Clinical Pharmacology in Psychiatry. Psychopharmacology Series, vol 10. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78010-3_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-78010-3_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-78012-7
Online ISBN: 978-3-642-78010-3
eBook Packages: Springer Book Archive